Home > Newsletters > The QMN Weekly Bulletin > DPT Lakewood Warned Over Investigation Flubs, Sterility
The QMN Weekly Bulletin
Sept. 14, 2012 | Vol. 4 No. 37
DPT Lakewood Warned Over Investigation Flubs, Sterility
DPT Laboratories’ investigations into batch failures at its Lakewood, N.J., plant are inadequate and heighten concern about microbiological contamination of topical drugs, according to an FDA warning letter. After six lots of the contract manufacturer’s Santyl ointment and one process validation lot were flagged for 12-month stability concerns in May 2011, additional lots of the product continued to fail for sterility — recurrences that Lakewood’s failure investigations have not explained, the FDA said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.